Search
Menu
Home
HTB
2022
February
February 2022
Contents
Editorial
HTB: no. 1/2 (January/February 2022)
i-Base appeal: please support i-Base with £5 or £10 a month
Conference reports
CROI 2022 to only be virtual: programme online
Antiretrovirals
US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine
Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent
Guidelines
BHIVA interim guidance on long-acting cabotegravir and rilpivirine injections
Coinfections and complications
HIV-associated reductions in telomere length are stopped by effective ART
Drug resistance
Drug resistance profile of integrase inhibitors when treating HIV-2
Other news
EACS HIV Summer School 2022: Applications are open
COVID-19: investigational drugs
UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19
COVID-19: guidelines
IDSA update COVID-19 guidelines (January 2022)
Job vacancies
i-Base vacancy: HIV treatment advocate and information officer
PDFs
HTB: no. 1/2 – plus HIV and COVID-19 (7 February 2022)
HTB RSS
Early access
Kigala Call to Action: sign-on for IAS 2025 conference
1 July 2025
HIV organisations support trans and non-binary communities against the unworkable EHRC guidelines
30 June 2025
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
28 June 2025
Clinical studies of two once-weekly pipeline compounds put on hold
27 June 2025
All early access reports
Current issues
July 2025
June 2025
May 2025
Back issues
Special report
Kigala Call to Action: sign-on for IAS 2025 conference
1 July 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate